Die Inhalte stammen aus dem NEJM Journal Watch Oncology & Hematology, der von der NEJM Group, a Division of the Massachusetts Medical Society, hergestellt und veröffentlich wird. Alle Rechte sind vorbehalten und alle Inhalte sind urheberrechtlich geschützt. Universimed und unsere Sponsoren ermöglichen Ihnen den Zugang zu diesen Inhalten als professionelle Unterstützung.
Promise of Gene Therapy for Hemophilia A and B
In two single-arm phase 3 trials, gene therapy was effective in reducing bleeding at ≈2 years, but questions about long-term durability and safety remain.
Rucaparib vs. Standard-of-Care Therapies in Metastatic, Castration-Resistant Prostate Cancer
Progression-free survival was longer with rucaparib than with physician's choice of therapy in patients with MCRPC and BRCA mutations.
Omission of Radiation Therapy in Older Patients with Breast Cancer
Omission of whole-breast RT was associated with higher incidence of recurrence but no difference in survival in patients with lower-risk, ER-positive cancer.
ASCO Gastrointestinal Cancers Symposium 2023 — Meeting Report
Highlights of the latest research in hepatocellular, pancreatic, biliary, colon, and gastroesophageal cancer.
Is There a Role for Adjuvant Immunotherapy in High-Risk Resected Renal Cell Carcinoma?
In patients with high risk for recurrence after nephrectomy, adjuvant nivolumab plus ipilimumab offered no disease-free survival advantage over placebo.
Sublobar Resection Is Now Standard of Care for Some Patients with Early-Stage NSCLC
Sublobar resection is noninferior to lobectomy in patients with carefully staged, peripheral cT1aN0 NSCLC and should be offered to them.
Efanesoctocog Alfa Shows Promise for Severe Hemophilia A Therapy
Among the benefits of treatment with this recombinant factor VIII product were fewer bleeding episodes, improved joint health, and reduced treatment burden.
Adjuvant S-1 Therapy After Resection of Biliary Cancer
Treatment with this oral fluorinated pyrimidine led to a modest survival advantage over observation.
A Next-Generation FGR2 Inhibitor for Intrahepatic Cholangiocarcinoma
Patients with advanced disease and FGFR2 alterations treated with the FGFR2 inhibitor futibatinib had a 42% response rate.